Isoray (NYSE:ISR) posted second-quarter results this week that were in line with estimates on Wall Street.
The Richland, Washington–based brachytherapy company reported losses of $1.6 million, or -1¢ per share, on sales of $2.82 million for the three months ended Dec. 31, 2021, for a sales growth of 19.4% compared with Q2 2021.
Earnings per share were -1¢, in-line with estimates on The Street, where analysts were looking for sales of $2.8 million.
“This quarter represents the third straight quarter of year over year growth for our core prostate business and other treatment areas including brain, head and neck, and lung cancers. In reviewing this quarter’s results and looking toward the future, we believe the strategies we have been implementing are working and will continue to have a positive impact. We believe Isoray is well-positioned to accelerate our growth as our end markets rebound further from the ongoing effects of the pandemic,” CEO Lori Woods said in a news release.
Isoray did not provide a financial outlook for the remainder of the fiscal year.
Shares in ISR were up 2.73% to 39¢ apiece in mid-morning trading.